Home › NDC Lookup › Ingredients › Nystatin Ointment › 00713-0686-31
Nystatin 100000 [USP'U]/g Ointment — NDC 00713-0686-31 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

Nystatin 100000 [USP'U]/g Ointment — NDC 0713-0686-31 (Billing 00713-0686-31)

by Cosette Pharmaceuticals, Inc. · 1 TUBE in 1 CARTON / 30 g in 1 TUBE

This is a package of Nystatin 100000 [USP'U]/g Ointment from Cosette Pharmaceuticals, Inc., marketed since Oct 2017 and currently FDA-listed; retail pharmacies pay about $0.2375 per g (NADAC). It is the main listing for this product, which comes in 2 package sizes.

NDC 00713-0686-31
🏷️ FDA NDC (as labeled) 0713-0686-31 billing pads the labeler segment with a zero
This package
Contains30 g in 1 tube Cost per g$0.2375 NADAC Per package$7.13 / 30 g Pack sizes2 compare ↓
Also priced by: Medicaid pays $0.4580/unit · Part D plans $0.4011/unit — full pricing hub ↓
Main listing for product 0713-0686 · Also comes in: 15 g 0713-0686-15
Rx only Generic On market Non-controlled ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

NDC database record

One package, one record: these facts belong to NDC 0713-0686-31 alone.

Record
FDA NDC Directory package listing · Human prescription drug
Code segments
0713 labeler · 0686 product · 31 package
Package marketed since
Jul 30, 2018
Sample package
No — commercial package
Listing certified through
Dec 31, 2026
Barcode (UPC-A, from the NDC)
3 0713068631 0
Medicaid fills, this package
92,008 prescriptions in the last four reported quarters
FDA record last changed
Jul 24, 2026

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 0713-0686-31
Product NDC 0713-0686
11-digit billing NDC 00713068631
NCPDP billing unit GM — per gram (weight)
RxCUI 884308
UNII BDF1O1C72E
Application # ANDA209114
SPL Set ID 8f87de59-33f2-32af-ae17-78bf30fb424d
Established class (EPC) Polyene Antifungal
Chemical class Polyenes
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2017-10-06
Route TOPICAL
Dosage form OINTMENT
Substance NYSTATIN
TE code (Orange Book) AT · RLD · RS

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 90150080004215
GPI class Nystatin
GCN Seq No 007283
GCN 30150
HICL code 004129
Ingredient (HICL) Nystatin
HIC1 code Q
Therapeutic class — broad (HIC1) Ear/Eye/Nose/Rectum/Topical/Vagina/Other
HIC2 code Q5
Therapeutic class — intermediate (HIC2) Agents Acting Principally On The Skin
HIC3 code Q5F
Therapeutic class — specific (HIC3) Topical Antifungals
AHFS code 08:14.28.00
AHFS class Polyene Antifungals
FDB label name NYSTATIN 100,000 UNIT/GM OINT
FDB brand name Nystatin
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 007283
  • GCN: 30150
  • GPI-14 (Medi-Span): 90150080004215
  • HICL (First Databank): 004129
  • AHFS class code: 08:14.28.00
  • RxCUI (RxNorm): 884308
Why two NDCs? The FDA registers this code as 0713-0686-31 — a 4-4-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the labeler segment → 00713-0686-31. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Polyene Antifungal class.

Pharmacologic class Polyene Antifungal
Drug family (ATC) Antibiotics, Antibiotics, Antibiotics
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name NYSTATIN 100,000 UNIT/GM OINT Ingredient Nystatin
📖 What it is MedlinePlus · NLM

Topical nystatin is used to treat fungal infections of the skin. Nystatin is in a class of antifungal medications called polyenes. It works by stopping the growth of fungi that cause infection.

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • It treats Candida yeast infections. Creams, ointment and powder are for the skin. The liquid is for the mouth. Tablets are for the digestive tract lining.
  • Place half the dose in each side of your mouth and keep it there as long as you can before swallowing. For babies, use the dropper and avoid feeding for 5 to 10 minutes. Keep going...
  • How do I use the liquid for a mouth infection?
  • Cream and ointment are usually applied twice a day. Powders are used two or three times a day. Keep using it until the area has healed, and follow your prescriber’s directions.
📖 Read our full Nystatin guide →

Supplement & herbal interactions

🌿 Drug–supplement interaction checker →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer gPer package
Retail pharmacies payNADAC · weekly $0.238 $7.13 / 30 g
Medicaid paysCMS SDUD · 12 mo $0.4580 $13.74 / 30 g
Medicare drug plans payPart D · Q2 2026 $0.4011 $12.03 / 30 g
NADAC price history (per g) — tap or hover for the price & month
Jan 2022 Aug 2022 Jan 2026 Sep 2026 $0.314 $0.238
▼ Down 16% over the last 24 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startMarketing endStatus
00713-0686-15 0713-0686-15 1 TUBE in 1 CARTON / 15 g in 1 TUBE $0.2331 / g $3.50 2018-07-30 — Active
00713-0686-31 You're viewing this Main listing 1 TUBE in 1 CARTON / 30 g in 1 TUBE $0.2375 / g $7.13 2018-07-30 — Active

In Medicaid, this is the most-dispensed pack of this product — about 69% of fills over the last four reported quarters. See all packs ↓

Pack size FAQ

What quantity is in this package?
This package is listed by the FDA — 1 tube in 1 carton / 30 g in 1 tube.
What NDC number is used to bill for this package of Nystatin 100000 [USP'U]/g Ointment?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Nystatin 100000 [USP'U]/g 00472-0166-15 Actavis 1 tube $0.233 AT Availability likely save 2%
Nystatin 100000 U/g 13668-0534-01 Torrent 15 g $0.233 AT Availability likely save 2%
Nystatin 100000 1/g 33342-0481-15 Macleods 1 tube $0.233 AT Availability likely save 2%
Nystatin 100000 U/g 72578-0089-01 Viona 15 g $0.233 AT Availability likely save 2%
Nystatin 100000 [USP'U]/gthis 00713-0686-31 Cosette 1 tube $0.238 AT Availability likely —
Nystatin 100000 [USP'U]/g 45802-0048-11 Padagis 1 tube $0.238 AT Availability likely —
Nystatin 100000 [USP'U]/g 69315-0307-15 Leading 1 tube $0.334 AT FDA listed +41%
Nystatin 100000 U/g 50090-5845-00 A-S 15 g — AT FDA listed —
Nystatin 100000 [USP'U]/g 63187-0464-15 Proficient 1 tube — AT FDA listed —
Nystatin 100000 U/g 63629-2515-01 Bryant 30 g — AT FDA listed —
Nystatin 100000 U/g 63629-2516-01 Bryant 15 g — AT FDA listed —
Nystatin 100000 U/g 70771-1357-01 Zydus 15 g — AT FDA listed —
Nystatin 100000 [USP'U]/g 71205-0437-15 Proficient 1 tube — AT FDA listed —
Nystatin 100000 U/g 72162-2007-02 Bryant 15 g — AT FDA listed —
Nystatin 100000 [USP'U]/g 72162-2333-02 Bryant 1 tube — AT FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2017
On the market since
Oct 2017
📍
2026
Currently FDA-listed
9 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

🧪 Avoiding an ingredient? See Nystatin inactive ingredients by manufacturer: every current product's list side by side, so you can ask your pharmacy for the version that does not list it.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII 4T6H12BN9U
    Petrolatum is a purified mineral oil-based jelly derived from petroleum. In medicines, it acts as an emollient, lubricant, and moisture barrier to soften skin, reduce friction, and help prevent water loss from formulations.

1 inactive ingredient listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerCosette Pharmaceuticals, Inc.
Application holderCOSETTE PHARMACEUTICALS INC
FDA applicationANDA209114 (ANDA)
Labeler code00713
First marketedOct 2017
Product typeHuman Prescription Drug
Portfolio99 products on file

More NDCs from Cosette Pharmaceuticals, Inc. labeler code 00713

The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⛔ Contraindications 🤒 Adverse Reactions 🧬 Clinical Pharmacology 📦 How Supplied / Storage and Handling 📋 Description ⚠️ Precautions 🧬 Pharmacokinetics 📄 Package Label / Principal Display Panel
🎯 Indications and Usage 38 words ▾

INDICATIONS AND USAGE Nystatin Ointment, USP is indicated in the treatment of cutaneous or mucocutaneous mycotic infections caused by Candida albicans and other susceptible Candidaspecies. Nystatin Ointment, USP is not indicated for systemic, oral, intravaginal or ophthalmic use.

⏱️ Dosage and Administration 26 words ▾

DOSAGE AND ADMINISTRATION Nystatin Ointment Adults and Pediatric Patients (Neonates and Older): Apply liberally to affected areas twice daily or as indicated until healing is complete.

⛔ Contraindications 17 words ▾

CONTRAINDICATIONS Nystatin Ointment is contraindicated in patients with a history of hypersensitivity to any of their components.

🤒 Adverse Reactions 58 words ▾

ADVERSE REACTIONS The frequency of adverse events reported in patients using Nystatin Ointment preparations is less than 0.1%. The more common events that were reported include allergic reactions, burning, itching, rash, eczema, and pain on application. (See PRECAUTIONS: General. ) To report SUSPECTED ADVERSE REACTIONS, contact Cosette Pharmaceuticals, Inc. at 1-800-922-1038 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch .

🧬 Clinical Pharmacology 157 words ▾

CLINICAL PHARMACOLOGY Pharmacokinetics Nystatin is not absorbed from intact skin or mucous membrane. Microbiology Nystatin is an antibiotic which is both fungistatic and fungicidal in vitro against a wide variety of yeasts and yeast-like fungi, including Candida albicans, C. parapsilosis, C. tropicalis, C. guilliermondi, C. pseudotropicalis, C. krusei, Torulopsis glabrata, Tricophyton rubrum, T. mentagrophytes. Nystatin acts by binding to sterols in the cell membrane of susceptible species resulting in a change in membrane permeability and the subsequent leakage of intracellular components.

On repeated subculturing with increasing concentrations of nystatin, Candida albicans does not develop resistance to nystatin. Generally, resistance to nystatin does not develop during therapy. However, other species of Candida ( C. tropicalis, C. guilliermondi, C. krusei, and C. stellatoides ) become quite resistant on treatment with nystatin and simultaneously become cross resistant to amphotericin as well.

This resistance is lost when the antibiotic is removed. Nystatin exhibits no appreciable activity against bacteria, protozoa, or viruses.

📦 How Supplied / Storage and Handling 56 words ▾

HOW SUPPLIED Nystatin Ointment, USP (100,000 USP Nystatin Units per gram) is a light yellow to yellow ointment available as follows: NDC 0713-0686-15 15 gram tube NDC 0713-0686-31 30 gram tube Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Distributed by: Cosette Pharmaceuticals, Inc. South Plainfield, NJ 07080 8-0686CPLNC3 Rev.03/2022 VC7623

📋 Description 58 words ▾

DESCRIPTION Nystatin Ointment, USP is for dermatologic use. Nystatin Ointment, USP for topical use only, contains 100,000 USP nystatin units per gram, in a white petrolatum base. Nystatin is a polyene antifungal antibiotic drug obtained from Streptomyces nursei . The structural formula is as follows: Molecular Weight 926.13 Molecular Formula C 47 H 75 NO 17 image description

⚠️ Precautions ~1 min read ▾

PRECAUTIONS General Nystatin Ointment should not be used for the treatment of systemic, oral, intravaginal or ophthalmic infections. If irritation or sensitization develops, treatment should be discontinued and appropriate measures taken as indicated. It is recommended that KOH smears, cultures, or other diagnostic methods be used to confirm the diagnosis of cutaneous or mucocutaneous candidiasis and to rule out infection caused by other pathogens.

INFORMATION FOR THE PATIENT Patients using these medications should receive the following information and instructions: The patient should be instructed to use these medications as directed (including the replacement of missed doses). These medications are not for any disorder other than that for which they are prescribed. Even if symptomatic relief occurs within the first few days of treatment, the patient should be advised not to interrupt or discontinue therapy until the prescribed course of treatment is completed.

If symptoms of irritation develop, the patient should be advised to notify the physician promptly. Laboratory Tests If there is a lack of therapeutic response, KOH smears, cultures, or other diagnostic methods should be repeated. Carcinogenesis, Mutagenesis, Impairment of Fertility No long-term animal studies have been performed to evaluate the carcinogenic potential of nystatin.

No studies have been performed to determine the mutagenicity of nystatin or its effects on male or female fertility. Pregnancy: Teratogenic Effects Category C. Animal reproduction studies have not been conducted with any nystatin topical preparation.

It also is not known whether these preparations can cause fetal harm when used by a pregnant woman or can affect reproductive capacity. Nystatin topical preparations should be prescribed for a pregnant woman only if the potential benefit to the mother outweighs the potential risk to the fetus. Nursing Mothers It is not known whether nystatin is excreted in human milk.

Caution should be exercised when nystatin is prescribed for a nursing woman. Pediatric Use Safety and effectiveness have been established in the pediatric population from birth to 16 years. See DOSAGE AND ADMINISTRATION

🧬 Pharmacokinetics 11 words ▾

Pharmacokinetics Nystatin is not absorbed from intact skin or mucous membrane.

📄 Package Label / Principal Display Panel 57 words ▾

PRINCIPAL DISPLAY PANEL NDC 0713-0686-15 Nystatin Ointment, USP 100,000 USP Nystatin Units Per Gram 15 g Rx only FOR TOPICAL USE ONLY. NOT FOR OPHTHALMIC USE. Cosette Pharmaceuticals, Inc. NDC 0713-0686-31 Nystatin Ointment, USP 100,000 USP Nystatin Units Per Gram 30 g Rx only FOR TOPICAL USE ONLY. NOT FOR OPHTHALMIC USE. Cosette Pharmaceuticals, Inc. 15gm-carton 30gm-carton

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
92K
Units reimbursed last 4 qtrs
3.1M
Gross reimbursed last 4 qtrs
$1.42M
Avg / prescription
$15.43
Avg / unit
$0.4580
Latest quarter Q1 2026
19.8KRx
Medicaid pays / g
$0.4580
gross reimbursed
vs
NADAC / g
$0.2375
acquisition cost
=
Spread
+$0.2205
+93% vs cost
What Medicaid paid per g (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
40% FFS 60% MCO
Fee-for-service · 36,910 Rx Managed care · 55,098 Rx
State Medicaid map
Alaska: no data reported AK Maine: 11,850 units · 849 per 100k residents ME Washington: 26,848 units · 344 per 100k residents WA Idaho: 12,120 units · 617 per 100k residents ID Montana: 6,583 units · 582 per 100k residents MT North Dakota: 3,410 units · 436 per 100k residents ND Minnesota: 43,307 units · 755 per 100k residents MN Wisconsin: 88,492 units · 1,497 per 100k residents WI Michigan: 103,453 units · 1,031 per 100k residents MI New York: 388,270 units · 1,984 per 100k residents NY Vermont: 5,370 units · 830 per 100k residents VT New Hampshire: no data reported NH Oregon: 11,085 units · 262 per 100k residents OR Nevada: 11,460 units · 359 per 100k residents NV Wyoming: 1,860 units · 318 per 100k residents WY South Dakota: 10,228 units · 1,113 per 100k residents SD Iowa: 103,500 units · 3,227 per 100k residents IA Illinois: 174,856 units · 1,393 per 100k residents IL Indiana: 22,776 units · 332 per 100k residents IN Ohio: 128,318 units · 1,089 per 100k residents OH Pennsylvania: 78,256 units · 604 per 100k residents PA New Jersey: 12,525 units · 135 per 100k residents NJ Massachusetts: 28,350 units · 405 per 100k residents MA California: 183,855 units · 472 per 100k residents CA Utah: 12,885 units · 377 per 100k residents UT Colorado: 37,191 units · 633 per 100k residents CO Nebraska: 30,988 units · 1,567 per 100k residents NE Missouri: 91,400 units · 1,475 per 100k residents MO Kentucky: 90,304 units · 1,995 per 100k residents KY West Virginia: 18,308 units · 1,034 per 100k residents WV Virginia: 19,992 units · 229 per 100k residents VA Maryland: 41,418 units · 670 per 100k residents MD Connecticut: 43,500 units · 1,203 per 100k residents CT Rhode Island: 5,610 units · 512 per 100k residents RI Arizona: 35,970 units · 484 per 100k residents AZ New Mexico: 37,665 units · 1,782 per 100k residents NM Kansas: 14,515 units · 494 per 100k residents KS Arkansas: 35,370 units · 1,153 per 100k residents AR Tennessee: 154,039 units · 2,162 per 100k residents TN North Carolina: 179,265 units · 1,654 per 100k residents NC South Carolina: 30,720 units · 572 per 100k residents SC Delaware: 34,380 units · 3,335 per 100k residents DE Oklahoma: 50,708 units · 1,251 per 100k residents OK Louisiana: 99,495 units · 2,175 per 100k residents LA Mississippi: 47,535 units · 1,617 per 100k residents MS Alabama: 67,155 units · 1,315 per 100k residents AL Georgia: 64,020 units · 580 per 100k residents GA D.C.: no data reported DC Hawaii: no data reported HI Texas: 201,040 units · 659 per 100k residents TX Florida: 191,591 units · 847 per 100k residents FL
Units reimbursed · per 100k residents
1353,335
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Delaware 3,335 /100k
2 Iowa 3,227 /100k
3 Louisiana 2,175 /100k
4 Tennessee 2,162 /100k
5 Kentucky 1,995 /100k
6 New York 1,984 /100k
7 New Mexico 1,782 /100k
8 North Carolina 1,654 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
1 tube this page00713-0686-31 92,008 Rx · $1,419,354
1 tube00713-0686-15 40,924 Rx · $503,220
Drug total (last 4 qtrs): 132,932 Rx · 4,051,374 units · $1,922,575 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Nystatin — the program that covers self-administered drugs. 22 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Nystatin. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$16.29M
Claims incl. refills
853.7K
Beneficiaries
614.3K
Spend / beneficiary
$26.52
Spend / claim
$19.08
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.
← 00713-0683-15 · Cosette 00713-0709-15 · Cosette →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.